^
Association details:
| Biomarker: | GFI1 36N |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1048 Impeding DNA Repair Offers a Novel Possibility for Personalized Therapy in AML Patients, Who Are Carrier of the Growth Factor Independence 1 Variant “GFI1-36N”
Published date:
11/04/2020
Excerpt:
Furthermore, TMZ in combination with Olaparib (0.2 µM) selectively and synergistically targeted leukemic cells from murine models of human leukemia and primary human AML cells but not non-malignant GFI1-36N cells….Furthermore, our data underscored the possibility of selectively targeting GFI1-36N leukemic cells using two well-established drugs, TMZ and Olaparib.
Secondary therapy:
temozolomide
